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Abstract
Background: Few community urologists offer cancer patients the opportunity to participate in cancer clinical trials,
despite national guidelines that recommend it, depriving an estimated 260,000 urological cancer patients of
guideline-concordant care each year. Existing strategies to increase urologists’ offer of clinical trials are designed for
resource-rich environments and are not feasible for many community urologists. We sought to design an
implementation intervention for dissemination in under-resourced community urology practices and to compare its
acceptability, appropriateness and adoption appeal among trial-naïve and trial-experienced urologists.
Methods: We used a design-for-dissemination approach, informed by the Theoretical Domains Framework and
Behavior Change Wheel, to match determinants of the clinical trial offer to theoretically informed implementation
strategies. We described the implementation intervention in evaluation workshops offered at urology professional
society meetings. We surveyed participants to assess the implementation intervention’s acceptability and
appropriateness using validated instruments. We also measured adoption appeal, intention to adopt and previous
trial offer.
Results: Our design process resulted in a multi-modal implementation intervention, comprised of multiple
implementation strategies designed to address six domains from the Theoretical Domains Framework. Evaluation
workshops delivered at four meetings, convened five separate professional societies. Sixty-one percent of those
offered an opportunity to participate in the implementation intervention indicated intention to adopt. Average
implementation intervention acceptability and appropriateness ratings were 4.4 and 4.4 (out of 5), respectively.
Acceptability scores were statistically significantly higher among those offering trials compared to those not (p =
0.03). Appropriateness scores did not differ between those offering trials and those not (p = 0.24). After urologists
ranked their top three innovation attributes, 43% of urologists included practice reputation in their top three
reasons for offering clinical trials; 30% listed practice differentiation among their top three reasons. No statistically
significant differences were found between those who offered trials and those who did not among any of the
innovation attributes.
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Conclusions: LEARN|INFORM|RECRUIT is a promising implementation intervention to address low accrual to clinical
trials, poised for implementation and effectiveness testing. The implementation intervention is appealing to its
target audience and may have equal uptake among trial-naïve and trial-experienced practices.
Keywords: Implementation science, Design for dissemination, Health care delivery, Clinical practice guidelines,
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Background
Participation rates in clinical trials to develop new can-
cer therapies have been directly linked to improvements
in population-level outcomes for the subgroups of pa-
tients who participate in them [1]. However, only about
8% of cancer patients participate in trials, thwarting the
development of new therapies [2]. A study conducted
through the National Cancer Institute’s (NCI’s) National
Clinical Trials Network found that 18% of cancer trials
closed with low accrual or achieved less than 50% of
their target enrollment at 3 years or more after the start
of the trial [5]. In contrast, a large majority of cancer pa-
tients report willingness to participate [6–8], but may
never be offered the opportunity. Many cancer clinical
trials are conducted at National Cancer Institute-
designated cancer centers, academic centers and select
community oncology practices supported by the NCI
[9]. Yet relatively few cancer patients are treated at these
sites where clinical trials are available, resulting in less
than half of all cancer patients having access to trials [2,
10, 11]. These structural limitations in how cancer care
is delivered have recently been identified as the most im-
portant factor leading to low patient participation [2].
Structural constraints in cancer care delivery are particu-
larly limiting for urological cancer patients’ access to clinical
trials. Urological cancer accounts for one in every five
newly diagnosed cancers in the US each year, involving ap-
proximately 330,000 patients [12]. Most of these cancers
are diagnosed, and treatment paths established, by urolo-
gists, without input from medical oncologists to whom clin-
ical trial infrastructure is most often directed [13].
Although multidisciplinary care is common in the treat-
ment of some cancers [14, 15], multidisciplinary care in
urological cancers is less well established, and particularly
rare in community settings, where 80% of urological cancer
patients are treated [1, 14, 16–18]. Consequently, relative to
other cancer patients, approximately 260,000 urological
cancer patients may be less likely to be offered clinical trials
at the point of treatment decision-making and their treat-
ment plans are less likely to include the systematic clinical
trial consideration that is often part of multidisciplinary
case review [19–21]. Despite interventions which reach into
the community to increase access to cancer clinical trials
[16, 22–26], community urologists report little awareness
of the urological cancer trials available, even those available
in their local community. They are less likely to report
access to clinical trials than their academic counterparts
[13], and few report offering clinical trials to patients [26].
To address the structural challenges which limit cancer
patients’ access to clinical trials, thereby slowing the devel-
opment of effective cancer therapies, the American Cancer
Society in 2018 convened a national committee to make
recommendations for overcoming these hurdles [2, 28].
That committee ranked development of new strategies
targeting non-research sites to refer interested patients to
trial opportunities as a top priority [28].
Unfortunately, little research exists to guide the develop-
ment of implementation strategies aimed at research-naïve
providers. To date most research on physician referral to
clinical trials has focused on physicians at institutions
already engaged in research [6, 29–33]. However, physicians
with access to clinical trials may have needs that are differ-
ent than those who do not [34–36]. For example, commu-
nity urologists experienced in clinical trial referral describe
perceived barriers among their less experienced peers that
they know do not, in fact, exist in practice, suggesting that
different strategies may be required at different points
across the adoption to implementation continuum. For ex-
ample, strategies needed to facilitate adoption may need to
address perceptions of the potential impact on practice (e.
g., the myth of “losing patients”), whereas those needed to
facilitate implementation may need to address memory and
attention through reminders and workflow integration.
Thus, it is important to evaluate potential implementation
strategies, distinguishing these two levels of experience.
Research-naïve urologists in community practice have
reported willingness to try strategies to facilitate the
offer of cancer clinical trials in their practice, but also re-
port potential barriers in their ability to do so. Previous
research based on the Theoretical Domains Framework
(TDF) [37] has suggested that the offer of clinical trials
may be influenced by constructs in select TDF domains:
environmental resources; social influences; knowledge;
memory, attention and decision processes; social/profes-
sional role and identity; and beliefs about consequences.
Thus, an implementation intervention addressing these
behavioral determinants may be effective in increasing
the reach of clinical trials. Because the determinants
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were identified in rural-serving practices in a single state,
the degree to which the implementation intervention
would appeal to a broader group of urologists, particu-
larly those in other rural-serving communities and
minority-serving communities, was unknown. The
present study describes the development and appeal of
an implementation intervention addressing these behav-
ioral determinants.
Objective
The objective of this study was to apply an implementa-
tion science approach to develop an implementation
intervention to increase urology practices’ referral to
cancer clinical trials and to compare the acceptability,
appropriateness and appeal of the approach between
urologists naïve to clinical trials and those experienced
in offering clinical trials across a diverse group of ur-
ology practices in the South and Midwest United States.
Methods
We used a design-for-dissemination approach [38–40]
informed by the Behavior Change Wheel [41] to develop
an implementation intervention to address behavioral
determinants of offering clinical trials. We then pre-
sented the implementation intervention to a diverse
sample of urologists and surveyed them to evaluate the
implementation intervention’s acceptability, appropriate-
ness and appeal. The Institutional Review Board of a
Midwestern university reviewed and approved the study.
Implementation intervention development
We assembled a transdisciplinary team of urologists, im-
plementation scientists, education technologists and
communications experts to increase the likelihood that
the resulting approach would be adopted and used in
practice [38–40]. We followed the six steps of the Be-
havioural Change Wheel (Fig. 1) to: (1) define the prob-
lem in behavioral terms; (2) select the target behavior;
(3) specify the target behavior; (4) identify determinants
of the target behavior; (5) identify intervention options;
and (6) match behavioral-change techniques and mode
of intervention delivery to the intended users’ context
[42]. The Behaviour Change Wheel is derived from a
distillation of 19 frameworks of behavior change through
systematic literature review [42]. As others have noted,
the process was iterative [43], resulting in our final inter-
vention package and implementation strategies.
For Steps 1–3, we conducted narrative review of the
available literature, relied on interviews with urologists
about their decision-making processes in cancer care
[44–48], and elicited clinical experience of study team
members. Semi-structured qualitative interviews of 22
academic and community US urologists were conducted
at the 2015 American Urological Association (AUA) an-
nual meeting and by telephone, subsequent to the meet-
ing. As part of the larger study on barriers to a
particular treatment, interviews were transcribed and
coded and the cancer care delivery process was mapped
to understand the urology practice context.
Behavioral determinants to community urologists’
offer of clinical trials, needed for Step 4, were collected
according to the TDF and reported elsewhere [26].
Briefly, we conducted semi-structured interviews of urol-
ogists and urology staff in rural-serving community ur-
ology practices in Kansas. Participation was limited to
practices which had urological oncology trials open lo-
cally at the time of the interview. We analyzed the data,
applying template analysis using a codebook of TDF
constructs. The results were also used to understand the
clinical trial referral process in behavioral terms (Step 1)
and context surrounding the behavior (Step 6).
For each determinant identified in the previous study
as salient, we selected intervention functions or policy
categories from the Behavior Change Wheel’s list of nine
functions and seven policy categories (Step 5). Finally, in
Step 6 we reviewed behavioral-change techniques to
identify those most relevant to each function or policy
and simultaneously considered the best mode of delivery
to arrive at theoretically supported implementation strat-
egies to deliver the components. Selection was informed
by feasibility and opportunities in the local communities
in which urologists practiced. We interviewed cancer
centers in the communities of urology practices partici-
pating in the determinants study about their willingness
and experience engaging urology practices. We used a
strategic planning approach and assessed their responses
to identify strengths, weakness, threats and opportunities
for supporting urology practice efforts. Thus, feasibility
Fig. 1 Six steps of implementation intervention development
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of potential approaches was used to inform the identifi-
cation of optimal intervention options to address
practice-identified determinants of referral and to select
the most potentially effective behavioral-change tech-
niques and modes of intervention delivery.
Implementation intervention evaluation
Evaluation approach
We created a workshop to present and test the appeal of
the implementation intervention. The didactic workshop
included evidence-based educational content about the
value of clinical trials from a health care providers’ per-
spective, including the impact on the practice, the clin-
ical workflow and the patient-provider relationship.
Other content described the implementation interven-
tion components. Educational content was delivered by
community oncologists who were members of the local
professional societies to which they were presenting and
identified as influencers by organizers of the local meet-
ings. Information about the implementation intervention
was delivered by the implementation intervention devel-
opers. We organized the educational sessions in con-
junction with local urology professional society
meetings. Targeted urology professional societies served
both state and regional professional societies. We chose
multiple loco-regional venues over a single national
venue as the local meetings are preferred by community
urologists from smaller practices. The workshops were
offered to all prospective meeting attendees at each of
the meetings via letter to all urologists in the states
served by state societies, and via announcement through
the program booklet and meeting email communications
sent to regional society members. Prospective attendees
at the state meetings were offered US$50 gift cards for
participation in a 1-h meeting. Prospective attendees at
the regional meeting were offered CME credit for par-
ticipation in a 1.5-h workshop. The evaluation workshop
was delivered at four meetings, convening five separate
professional societies. The societies represented urolo-
gists across 10 states in the Midwest and South. Work-
shop location and placement within the official meeting
agenda varied.
Measures
Intervention appeal was evaluated via survey distributed
to a purposive sample of all workshop attendees (Add-
itional file 1). The survey instrument included three
scales to assess the appeal of the implementation inter-
vention and a single item assessing whether participants
currently offer clinical trials. We used the four-item, val-
idated scales, the Acceptability of Intervention Measure
(AIM) [49] and the Intervention Appropriateness Meas-
ure (IAM) [49] to measure acceptability and appropriate-
ness. We used a novel measure, the Attributes of
Innovation Adoption [47] scale to assess the implemen-
tation intervention’s appeal. All items were rated on a
Likert response scale ranging from 1 to 5 with higher
scores indicating greater acceptability, appropriateness,
or attribute appeal. Participants were asked to rank the
three innovation attributes that were most important to
them. We measured behavioral intent to adopt the im-
plementation intervention by asking participants to pro-
vide contact information for follow-up, collected
separately from the survey responses to protect confi-
dentiality. Due to capacity limitations, behavioral intent
was only measured when and where there was capacity
to deliver the implementation intervention.
Analysis
To calculate the acceptability and appropriateness
scores, we summed the Likert ratings and averaged them
across the four items. Each innovation attribute was
scored individually. Ratings greater than 3.0 were con-
sidered salient to adoption. Student’s t test was used to
assess differences by current offer of clinical trials. We
combined the top ranked innovation attributes and cal-




Step 1. Define problem in behavioral terms
Narrative literature review suggested that patients do
not participate in clinical trials due to a number of rea-
sons. Often, they are asked too late in the process, after
treatments have already been decided upon [50] or initi-
ated [51]. Thus, ensuring that clinical trials be consid-
ered as a treatment option at the point of initial
treatment decision-making is critical. Therefore, we ar-
ticulated the clinical trial issue from a community urolo-
gists’ workflow (Fig. 2) to identify the ideal time to place
clinical trials and provide scaffolding to understand lack
of accrual from a behavioral perspective. In typical prac-
tice, potential cancer patients present for biopsy and re-
turn for treatment counseling, either in conjunction with
result presentation or following telephoned results. Urol-
ogists devise a preliminary treatment recommendation
upon reviewing the results, the timing of which varies by
practice. This treatment recommendation is presented
and discussed with the patient at a treatment counseling
visit and a treatment is scheduled, sometimes with add-
itional visits for discussion of treatment options.
The target for behavior change was identified as the
urologist. Urologists and staff agree that identifying and
discussing treatment options falls within the professional
responsibilities of the urologist [19]. However, physicians
require motivation to include trials in their assessment
and awareness of what trials are available [26, 52, 53].
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To incorporate trials as a treatment option into treatment
counseling, they need knowledge and skills to initiate the
conversation, often lacking among most physicians who
have little exposure to trials in their medical training.
A structural barrier to clinical trial accrual arises
because most trial participation models require a prac-
tice to undergo an intensive process to obtain human
subject credentialing, and make substantial additional
investments in learning about trials, opening them in
their practice, and conducting extensive data collection
[54]. This may be an unrealistic expectation for many
providers, but particularly for community-practicing
urologists focused solely on clinical service provision.
Based on the willingness to engage in the low-intensity
efforts we observed in our qualitative study, we recon-
ceptualized the target behavior as referral for eligibility
screening, rather than eligibility screening itself. To
execute the referral, urologists need trusted referral part-
ners to whom they can refer. They also need a mechan-
ism by which they can efficiently communicate with the
referral partner to ensure that patient care—for which
they are ethically and legally responsible—is delegated
appropriately [26].
Step 2. Select target behavior
Having defined the problem in behavioral terms, we thus
selected the target behaviors as: (1) considering clinical
trials as a treatment option; (2) treatment counseling in-
clusive of clinical trials; (3) the act of referral; and (4)
cancer program communication (Fig. 2).
Step 3. Specify target behavior
We specified each target behavior based on our inter-
views with community urologists and their staff, with
particular attention paid to aligning the behaviors with
the professional roles and identities perceived among
both physicians and staff [26]. Table 1 illustrates for
each target behavior who, what, when, where, how often,
and with whom each behavior should occur. For simpli-
city, we recommend that urologists should consider,
counsel and refer all newly diagnosed cancer patients
for clinical trial eligibility screening. Consideration
should occur at review of biopsy results using the broad
eligibility criteria provided by the trial expert in the nor-
mal location of review. The referral should occur at the
treatment counseling visit prior to patient decision on
treatment. Notification of the referral to the cancer pro-
gram should occur immediately following referral and
could be delegated to clinic staff.
Step 4. Identify determinants of behavior
Previous work identified six of the 14 TDF domains as
most salient for community urologists’ initial adoption
of the four key clinical trial behaviors [19]. In particular,
community urologists could be highly motivated by ur-
ology peers and professional societies to offer clinical tri-
als. They believed that their trial involvement could
accrue positive social consequences to their practice by
differentiating their practice from others. They saw re-
ferral to a trial specialist as a natural alignment with the
current practice of referring cancer patients to specialists
in other treatment modalities (e.g., radiation oncologist).
They acknowledged the need for concise trial informa-
tion to consider trials as a treatment option, and brief
skills training to counsel patients. They needed re-
minders of trial opportunities at the point of care and
support for their patients, not only to prepare them for
treatment counseling, but also to help them understand
the referral process.
Step 5. Identify intervention options
We mapped each determinant to an empirically or the-
oretically supported intervention function or policy cat-
egory from the Behavior Change Wheel. Table 2 lists the
Fig. 2 Process map to identify and select target behaviors (Step 1)
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key determinants and each determinants’ COM-B cat-
egory in columns 1 and 2, and the corresponding inter-
vention functions and policies in columns 3 and 4.
Step 6. Identify behavior-change techniques and
implementation options
For each intervention function or policy needed, our team
brainstormed behavior-change techniques and potentially
effective modes of delivery. These were iteratively shaped
while reviewing opportunities available in the community
or within national support structures and considering the
contextual determinants in community practice. Columns
5 and 6 of Table 2 list the behavior-change techniques
and specific mode of delivery.
Our design process resulted in a multi-modal implemen-
tation intervention comprised of multiple implementation
strategies. Together, this set of strategies is called LEARN|
INFORM|RECRUIT and includes continuing education
workshops, newsletters, clinical trial reminders, point-of-
care materials, referral tools, referral network building and
patient-support materials. It is available to practices inter-
ested in adopting the program in controlled evaluation
studies at learn-inform-recruit.org. Upon enrollment,
LEARN|INFORM|RECRUIT is made available as an imple-
mentation intervention tailored to each practice through
personalization of trial opportunities available in the local
community, development of a dedicated referral pathway to
the cancer center, and practice branding of patient-facing
materials. It is externally facilitated by trained study staff
through a mixture of in-person, telephone and electronic
communications delivered in the practice setting and sup-
ported by a non-public website of video content. Other
Table 1 Specification of the behavior
Step 2 Step 3
Select target behavior Specify target behavior
Consider Who? Urologist
What? Clinical trial as a treatment option
When? Prior to treatment decision
Where? At location of results review
How often? At each cancer diagnosis
With whom? Each diagnosed cancer patient
Counsel Who? Urologist
What? Clinical trials are a treatment option
When? At first treatment counseling visit
Where? In the exam room
How often? Every initial cancer treatment
counseling visit
With whom? All patients meeting broad eligibility
criteria (determined by flow sheet)
Refer Who? Urologist
What? Signal to patient and cancer program that
patient is recommended for clinical trial eligibility screening
When? During and immediately following treatment counseling visit
Where? Exam room and location where charting is performed
How often? Each time clinical trial is included in treatment counseling
With whom? All patients meeting broad eligibility criteria (determined
by flow sheet) who do not refuse referral
Notify Who? Urologist or designated clinic staff
What? Cancer patient is scheduling visit for clinical
trial eligibility screening
When? At patient’s convenience in next 3 weeks
Where? Immediately following treatment counseling visit
How often? Each time referral is documented
With whom? All patients meeting broad eligibility criteria
(determined by flow sheet) who do not refuse referral
Step 1 is illustrated in Fig. 2. Steps 4–6 are illustrated in Table 2
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Table 2 Mapping of behavioral determinants to intervention options and content and implementation options
Step 4 Step 5 Step 6
Determinants of referral Intervention options Content and implementation options
COM-B TDF Intervention
functions









(practical), instruction on how to
perform the behavior, information
about social and environmental
consequences, demonstration of
the behavior, information about
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champion and endorsed by
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on how to perform the behavior,
information about social and
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approval, credible source, social
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environment, instruction on how
to perform behavior (patient)
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Feedback on outcome of GU Trial Chart Note
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materials are printed for the practices’ convenience and
mailed to the practice at program launch and when updates
are necessary (e.g., opening of new clinical trials).
Implementation intervention evaluation
Response
Characteristics of the evaluation workshops, audience
size and participation are presented in Table 3. Across
the four workshops 67 participants registered attendance
(15% of all professional society meeting attendees). Fifty-
four participants across the four meetings evaluating the
implementation intervention provided evaluations with
no missing data (81% response rate). Among them, 78%
reported currently offering trials at their practice.
Implementation intervention appeal
Among those attending the three workshops offering an
opportunity to participate in the implementation inter-
vention, 61% (33/54) asked to be contacted to participate
in the program. Potential adopters represented urology
practices from eight US states and two states in Mexico.
Urologists from eight of 10 US states that were targeted
as part of the evaluation workshop expressed interest in
adopting the program. A practice from a state not tar-
geted also expressed interest.
Intervention acceptability and appropriateness
Average implementation intervention acceptability and ap-
propriateness ratings were high: 4.4 and 4.4 (out of 5), re-
spectively (Table 4). Acceptability scores were statistically
Table 2 Mapping of behavioral determinants to intervention options and content and implementation options (Continued)
Step 4 Step 5 Step 6
Determinants of referral Intervention options Content and implementation options
COM-B TDF Intervention
functions
Policy categories Behavior-change techniques Mode of delivery Also
addressed in
…
behavior, information on how to
perform the behavior, information
about consequences
Generalization of target behavior Align role delineation with





Education Instruction on how to perform




Prompts/cues, social reward, non-
specific incentive
Branding through stationary,
pens, brochures and media
Step 1 is provided in Fig. 2. Steps 2 and 3 are provided in Table 1
All behavior-change techniques are directed at the urology provider, unless otherwise indicated in parentheses
AUA American Urological Association, COM-B Capability, Opportunity, Motivation and Behavior Model GU genitourinary, TDF Theoretical Domains Framework
Table 3 Evaluation workshop meeting characteristics
Site A Site B Site C Site D
Organizational sponsor scope State State State Regional
Meeting scope 1 state 2 states 1 state 8 US states, Mexico + Central America
Placement on meeting agenda Breakout Plenary No Breakout
Workshop location On-site On-site Off-site On-site
Recruitment strategy Letter Letter Letter Program + meeting PR
Number urologists invited 104 0 84 2189
Incentive US$50 US$50 US$50 CME Credit
Total meeting attendancea 54 41 N/Ad 341
Workshop attendance 10 (19%) 13 (32%) 9 (10%) 35 (10%)
Percent attendees non-academicb 35% 32% 67% 5%
Behavioral intent to adopt 10 –c 9 14
CME continuing medical education, N/A not applicable, PR Public relations
aMeeting attendance includes urologists and non-physician attendees
bProportion calculated on rostered attendees where data available
cNot offered opportunity to adopt due to capacity limitations
dData not available from Louisiana Urological Society; proportion attendance conservatively based on number of urologists invited
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significantly higher among those offering trials compared to
those not (p = 0.03). Appropriateness scores did not differ
between those offering trials and those not (p = 0.24).
Top-rated innovation attributes (Fig. 3) were: (1) help-
ing the urologist to match the right patient to right
treatment; (2) increasing a practice’s reputation as offer-
ing cutting-edge treatment options; (3) helping to make
care more patient-centered; (4) helping the urologist to
adhere to practice guidelines; (5) differentiating the urol-
ogists’ practice from other practices; (6) lessening the
patients’ risk of decisional regret; and (7) decreasing the
need to refer. No statistically significant differences were
found between those who offered trials and those who
did not among any of the innovation attributes. After
urologists ranked their top three innovation attributes,
43% of urologists included practice reputation in their
top three reasons for offering clinical trials; 30% listed
practice differentiation among their top three reasons.
Discussion
We developed an implementation intervention that is
viewed as highly acceptable and appropriate to profes-
sionally engaged urologists, a majority of whom indi-
cated an intention to adopt the program. The
implementation intervention potentially has broad reach,
as our participants represented both urban and rural,
and community and academic practices across a sizable
geographic portion of North America. Confirming our
implementation intervention design, which underscored
practice differentiation as a key motivator, participants
highly valued innovations which would set them apart
from other providers. Further, our design of the program
to position the offer of clinical trials as an expansion of
treatment options was validated by urologists’ high rat-
ings of matching the right patient to the right treatment
as an appealing innovation attribute. Because implemen-
tation intervention users have defined this idea of “preci-
sion medicine” as an expectation for an innovation that
they are willing to adopt, any future implementation
intervention effectiveness assessments should include
the approach’s ability to deliver on this expectation.
The program we designed is unique in multiple ways
among strategies to increase the offer of clinical trials.
First, it focuses on the structural disjuncture in the care
delivery environment that separates urological cancer pa-
tients from several guideline-based cancer services, includ-
ing clinical trials. In this way, it is designed to increase the
reach of clinical trials, a critical component of intervention
effectiveness [55]. Increasing reach may be particularly im-
portant in the current era of cancer clinical trials, where
precision medicine trials requiring higher levels of popula-
tion screening to identify eligible participants are gaining
dominance [56, 57]. Second, it leverages the existing pro-
fessional identities of community-based urologists. Rather
than requiring practices to provide the infrastructure to
open trials in their own practice, such as study personnel
and IRB regulatory requirements, it allows them to
capitalize on natural referral behaviors and expands their
networks to include trial experts. Other programs, such as
the Society of Urological Oncology-Clinical Trials
Table 4 Ratings of acceptability and appropriateness by prior offer of clinical trials
Average rating Prior offer of clinical trials No prior offer of clinical trials Significance (p level)
Acceptability 4.4 4.6 4.2 p = 0.03
Appropriateness 4.4 4.5 4.2 p = 0.24
n = 54
Higher scores indicate greater perceived acceptability and appropriateness
Fig. 3 Average rating of innovation adoption attributes across the sample, n = 54. Higher scores indicate greater agreement
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Consortium, cater to larger practices that can invest in re-
search infrastructure [22]. While successful, not all prac-
tices can provide this level of skill and capacity to meet
guideline recommendations. The National Cancer Insti-
tute’s Community Oncology Research Program, although
effective in expanding trial options to community pro-
viders [1, 58], focuses on oncology practices [16] and the
degree to which they effectively extend to non-oncology
cancer providers is not well understood [59]. Other initia-
tives mainly offer educational and navigational support for
patients [23, 24, 60–62] and rely on patient activation in a
patient-physician dynamic which weighs heavily toward
physician influence. Without recommendation of the
physician, few patients will participate in trials [6, 63]. Fi-
nally, our intervention is unique because, to our know-
ledge, it is the first to apply principles of implementation
science to the decades-old, intransigent problem of low
accrual to clinical trials. Continued research to assess its
effectiveness can further the developing field. Although
the implementation intervention was highly rated, we ob-
served some differentiation in its acceptability ratings be-
tween urologists experienced in offering clinical trials and
research-naïve urologists. While both rated the implemen-
tation intervention as highly acceptable, those with experi-
ence rated it significantly higher. Although the instrument
used to measure acceptability has been validated [64], this
is the first study, to our knowledge, to provide scores for a
population of potential adopters. Thus, scores have not
been normalized among other interventions or adopters,
providing little context in which to interpret either the rat-
ings observed in this study or their differentiation among
users. Future studies should compare ratings against those
found in this study. Nonetheless, we observed no differen-
tiation in ratings of appropriateness or individual attri-
butes of innovation appeal, suggesting that, perhaps, in
this sample of urologists, trial-naïve participants thought
that they should offer clinical trials, but may still see com-
ponents of the implementation intervention as not com-
pletely aligning with their practice ecology.
Moreover, there may be some motivational goals that
we have not identified. Attributes included in the meas-
ure were identified from qualitative interviews with urol-
ogists around treatment decision making in prostate
cancer and in the context of offering clinical trials [47].
The items remain to be validated in a larger sample of
providers. However, participants provided no additional
innovation attributes that promote adoption when
afforded the opportunity.
Our implementation intervention is designed on some
key assumptions. One is that community urologists are
not currently engaging their patients about clinical trials.
Although Ellis et al. reported recent qualitative data that
supports this [19], the last nationally representative survey
of urologists was conducted in 2005. By approaching
urologists through state professional societies, we reached
more providers who self-reported that they already offered
clinical trials than those who self-identified as trial-naive.
Thus, contemporary assessment of urologists’ involvement
in clinical trials is needed. Changes in both the clinical
trial landscape (i.e., growth of precision medicine trials, in-
creased presence of National Cancer Institute Community
Oncology Research Program (NCORP)) and urological
cancer care delivery (e.g., continued consolidation of prac-
tices, decline in solo practice, shortages of common blad-
der cancer therapies currently in clinical trial) may have
impacted urologists’ engagement in trials. One opportun-
ity is to query the NCI’s Community Oncology Research
Program to identify how many cancer components already
include urologists.
Finally, we report potential adopters’ assessment of the
acceptability, appropriateness and appeal of the imple-
mentation intervention, we did not test feasibility among
urology practices, effectiveness of the approach in in-
creasing referrals or accrual, or, importantly, the accept-
ability of the approach to cancer programs that are
essential partners in the implementation approach. Aca-
demic physicians and cancer center administrators and
staff will be critical partners supporting community phy-
sicians’ offer of trials. Thus, it is essential to assess these
partners’ engagement, and willingness to participate, and
to identify what successful strategies have already been
tried [65]. Further, future research should address the
degree to which cancer programs offering clinical trials
would welcome additional eligibility screening responsi-
bilities and measure the additional workload required.
Limitations
Our study is not without limitations. We developed and
tested the implementation intervention across the Midwest
and select Southern states and found it to be appealing.
However, results may not be generalizable. Whether the ap-
peal of the implementation intervention extends to other
practices awaits future opportunities to offer the program
in other regions of the country. Efforts to extend the imple-
mentation intervention to other regions of the country are
ongoing and should be rigorously tested with the appropri-
ate study design. A cluster-randomized trial can assess
whether an intervention informed by principles of imple-
mentation science can increase the rate of cancer patients’
participation. Secondly, our rigorous, theoretically based
implementation development process should promote
rapid adoption and implementation of the program. How-
ever, both whether the program will be adopted and the
predictive value of acceptability and appropriateness ratings
on subsequent adoption should be measured.
Finally, the application of the Behavior Change Wheel
is subjective and resulted in a large number of interven-
tion components. Although the framework is
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theoretically and empirically derived, mapping of
behavior-change techniques to specific determinants of
behavior is not yet an exact science. A great deal of het-
erogeneity in mapping the most appropriate technique
to a specific determinant has been observed [66]. Thus,
others may have categorized determinants, functions, or
behavior-change techniques differently. Members of our
team have experience with determinant coding and
some have training in behavior-change technique cod-
ing, which should promote concordance. Nonetheless,
the inability to empirically map the behavior-change
techniques to determinants underscores the need for ef-
fectiveness testing. Additional implementation research
can identify the core components of the implementation
intervention and inform future efforts to optimize those
implementation strategies.
Conclusions
Low-enrolling studies slow the uptake of innovations in
cancer care [2, 58], and are costly to study sponsors and
the institutions that conduct them [67]. We have devel-
oped a promising implementation intervention to ad-
dress this problem in an understudied segment of cancer
providers. The implementation intervention is appealing
to its target audience. Implementation intervention ef-
fectiveness and the effect of its acceptability, appropri-
ateness and appeal on the adoption of the offer of
clinical trials should be further tested.
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